Search

Your search keyword '"Branford, Susan"' showing total 25 results
Start Over Author "Branford, Susan" Publisher elsevier bv
25 results on '"Branford, Susan"'

1. Clonal Architecture of Donor-Derived Myeloid Neoplasms after Allogeneic Hematopoietic Stem Cell Transplant

Author

Wechalekar, Gauri, primary, Cibich, Ms. Alia, additional, Shanmuganathan, Naranie, additional, Kutyna, Monika, additional, Sekaran, Usha Chandra, additional, Singhal, Deepak, additional, Beligaswatte, Ashanka, additional, Purins, Leanne, additional, Hahn, Christopher Norman, additional, Yeung, David T, additional, Bardy, Peter, additional, Purtill, Duncan, additional, Bajel, Ashish, additional, Branford, Susan, additional, and Hiwase, Devendra, additional

Published
2024
Full Text
View/download PDF

2. Seronegative Rheumatoid Arthritis and Innate Immune Activation is Frequent in Myeloid Neoplasms with Isocitrate Dehydrogenase 1/2 Mutations

Author

Hong, Lih En, primary, Wechalekar, Mihir D., additional, Kutyna, Monika M., additional, Small, Annabelle, additional, Lim, Kelly, additional, Thompson-Peach, Chloe, additional, Li, Joule J., additional, Chhetri, Rakchha, additional, Scott, Hamish S., additional, Brown, Anna, additional, Hahn, Christopher N., additional, Yeung, David T., additional, Sajid, Salvia, additional, Robinson, Nirmal, additional, Thomas, Ranjeny, additional, Branford, Susan, additional, D'Andrea, Richard J., additional, Samaraweera, Saumya E., additional, Patnaik, Mrinal, additional, Proudman, Susanna, additional, Thomas, Daniel, additional, Kok, Chung Hoow, additional, Shah, Mithun V., additional, and Hiwase, Devendra K., additional

Published
2023
Full Text
View/download PDF

3. RNA-Based Targeted Gene Sequencing Improves the Diagnostic Yield of Mutant Detection in Chronic Myeloid Leukemia

Author

Shanmuganathan, Naranie, primary, Wadham, Carol, additional, Thomson, Daniel, additional, Shahrin, Nur Hezrin, additional, Vignaud, Chloe, additional, Obourn, Vanessa, additional, Chaturvedi, Shalini, additional, Yang, Feng, additional, Feng, Jinghua, additional, Saunders, Verity, additional, Kok, Chung H., additional, Yeung, David, additional, King, Rob M., additional, Kenyon, Rosalie R., additional, Lin, Ming, additional, Wang, Paul, additional, Scott, Hamish, additional, Hughes, Timothy, additional, Schreiber, Andreas W., additional, and Branford, Susan, additional

Published
2022
Full Text
View/download PDF

4. Standardized practices for RNA diagnostics using clinically accessible specimens reclassifies 75% of putative splicing variants

Author

Bournazos, Adam M., primary, Riley, Lisa G., additional, Bommireddipalli, Shobhana, additional, Ades, Lesley, additional, Akesson, Lauren S., additional, Al-Shinnag, Mohammad, additional, Alexander, Stephen I., additional, Archibald, Alison D., additional, Balasubramaniam, Shanti, additional, Berman, Yemima, additional, Beshay, Victoria, additional, Boggs, Kirsten, additional, Bojadzieva, Jasmina, additional, Brown, Natasha J., additional, Bryen, Samantha J., additional, Buckley, Michael F., additional, Chong, Belinda, additional, Davis, Mark R., additional, Dawes, Ruebena, additional, Delatycki, Martin, additional, Donaldson, Liz, additional, Downie, Lilian, additional, Edwards, Caitlin, additional, Edwards, Matthew, additional, Engel, Amanda, additional, Ewans, Lisa J., additional, Faiz, Fathimath, additional, Fennell, Andrew, additional, Field, Michael, additional, Freckmann, Mary-Louise, additional, Gallacher, Lyndon, additional, Gear, Russell, additional, Goel, Himanshu, additional, Goh, Shuxiang, additional, Goodwin, Linda, additional, Hanna, Bernadette, additional, Harraway, James, additional, Higgins, Megan, additional, Ho, Gladys, additional, Hopper, Bruce K., additional, Horton, Ari E., additional, Hunter, Matthew F., additional, Huq, Aamira J., additional, Josephi-Taylor, Sarah, additional, Joshi, Himanshu, additional, Kirk, Edwin, additional, Krzesinski, Emma, additional, Kumar, Kishore R., additional, Lemckert, Frances, additional, Leventer, Richard J., additional, Lindsey-Temple, Suzanna E., additional, Lunke, Sebastian, additional, Ma, Alan, additional, Macaskill, Steven, additional, Mallawaarachchi, Amali, additional, Marty, Melanie, additional, Marum, Justine E., additional, McCarthy, Hugh J., additional, Menezes, Manoj P., additional, McLean, Alison, additional, Milnes, Di, additional, Mohammad, Shekeeb, additional, Mowat, David, additional, Niaz, Aram, additional, Palmer, Elizabeth E., additional, Patel, Chirag, additional, Patel, Shilpan G., additional, Phelan, Dean, additional, Pinner, Jason R., additional, Rajagopalan, Sulekha, additional, Regan, Matthew, additional, Rodgers, Jonathan, additional, Rodrigues, Miriam, additional, Roxburgh, Richard H., additional, Sachdev, Rani, additional, Roscioli, Tony, additional, Samarasekera, Ruvishani, additional, Sandaradura, Sarah A., additional, Savva, Elena, additional, Schindler, Tim, additional, Shah, Margit, additional, Sinnerbrink, Ingrid B., additional, Smith, Janine M., additional, Smith, Richard J., additional, Springer, Amanda, additional, Stark, Zornitza, additional, Strom, Samuel P., additional, Sue, Carolyn M., additional, Tan, Kenneth, additional, Tan, Tiong Y., additional, Tantsis, Esther, additional, Tchan, Michel C., additional, Thompson, Bryony A., additional, Trainer, Alison H., additional, van Spaendonck-Zwarts, Karin, additional, Walsh, Rebecca, additional, Warwick, Linda, additional, White, Stephanie, additional, White, Susan M., additional, Williams, Mark G., additional, Wilson, Meredith J., additional, Wong, Wui Kwan, additional, Wright, Dale C., additional, Yap, Patrick, additional, Yeung, Alison, additional, Young, Helen, additional, Jones, Kristi J., additional, Bennetts, Bruce, additional, Cooper, Sandra T., additional, Abdulrasool, Ghusoon, additional, Al Eryani, Ghamdan, additional, Arts, Peer, additional, Bagnall, Richard, additional, Baker, Naomi L., additional, Barnett, Christopher, additional, Beecroft, Sarah, additional, Berbic, Marina, additional, Black, Michael, additional, Blackburn, Jim, additional, Blombery, Piers, additional, Bournazos, Adam M., additional, Branford, Susan, additional, Breen, Jimmy, additional, Burnett, Leslie, additional, Canson, Daffodil, additional, Cheong, Pak, additional, Chew, Edward, additional, Christodoulou, John, additional, Chung, Seo-Kyung, additional, Clark, Mike, additional, Cliffe, Corrina, additional, Cole, Melissa, additional, Collins, Felicity, additional, Compton, Alison, additional, Cooper, Antony, additional, Corbett, Mark, additional, Cowley, Mark, additional, Dudding, Tracy, additional, Eggers, Stefanie, additional, Eyras, Eduardo, additional, Fernandez, Miriam Fanjul, additional, Fellowes, Andrew, additional, Fleischer, Ron, additional, Folland, Chiara, additional, Fox, Lucy, additional, Gaff, Clara, additional, Galea, Melanie, additional, Ghaoui, Roula, additional, Gornanitis, Ilias, additional, Ha, Thuong, additional, Hayashi, Rippei, additional, Hayes, Ian, additional, Henderson, Alex, additional, Hesson, Luke, additional, Heyer, Erin, additional, Hildebrand, Michael, additional, Hipwell, Michael, additional, Hoskins, Cass, additional, Jackson, Matilda, additional, James, Paul, additional, Wong, Justin Jong-Leong, additional, Kassahn, Karin, additional, Kaub, Peter, additional, Kevin, Lucy, additional, Kumble, Smitha, additional, Kummerfeld, Sarah, additional, Laing, Nigel, additional, Lau, Chiyan, additional, Lee, Eric, additional, Leighton, Sarah, additional, Lundie, Ben, additional, Mayoh, Chelsea, additional, McGaughran, Julie, additional, McPhillips, Mary, additional, Meldrum, Cliff, additional, Middleton, Edwina, additional, Mina, Kym, additional, Nisselle, Amy, additional, Oates, Emily, additional, Oshlack, Alicia, additional, Parasivam, Gayathri, additional, Parsons, Michael, additional, Quinn, Michael, additional, Rasko, John, additional, Ravenscroft, Gina, additional, Ravine, Anja, additional, Recsei, Krista, additional, Rehn, Jacqueline, additional, Robertson, Stephen, additional, Ronan, Anne, additional, Ryland, Georgina, additional, Sadedin, Simon, additional, Schreiber, Andreas, additional, Scott, Hamish, additional, Scott, Rodney, additional, Semsarian, Christopher, additional, Simons, Cas, additional, Singer, Emma, additional, Smyth, Renee, additional, Spurdle, Amanda, additional, Sullivan, Patricia, additional, Sundercombe, Samantha, additional, Thorburn, David, additional, Toubia, John, additional, Trent, Ronald, additional, Tudini, Emma, additional, Voneague, Irina, additional, Waddell, Leigh, additional, Walker, Logan, additional, Wallis, Mathew, additional, Warnock, Nick, additional, Weatheritt, Robert, additional, White, Deborah, additional, Winship, Ingrid, additional, Worgan, Lisa, additional, Wu, Kathy, additional, and Ziolowski, Andrew, additional

Published
2022
Full Text
View/download PDF

5. CML-109: Exploratory Biomarker Analysis from ENESTnd: Gene Expression Signature Distinguishes Deep Molecular Response (DMR) from Poor Response in Chronic Myeloid Leukemia (CML)

Author

Radich, Jerald, primary, Larson, Richard, additional, Kantarjian, Hagop, additional, Deininger, Michael, additional, Pinilla-Ibarz, Javier, additional, DeAngelo, Daniel, additional, Branford, Susan, additional, Sadek, Islam, additional, Chaturvedi, Shalini, additional, Wall, Matthew, additional, Mishra, Kaushal, additional, Purkayastha, Das, additional, Shrestha, Alok, additional, Obourn, Vanessa, additional, White, Brian, additional, and Druker, Brian, additional

Published
2020
Full Text
View/download PDF

10. Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study

Author

Hiwase, Devendra, primary, Tan, Peter, additional, D’Rozario, James, additional, Taper, John, additional, Powell, Anthony, additional, Irving, Ian, additional, Wright, Matthew, additional, Branford, Susan, additional, Yeung, David T., additional, Anderson, Luke, additional, Gervasio, Othon, additional, Levetan, Carly, additional, Roberts, Will, additional, Solterbeck, Ann, additional, Traficante, Robert, additional, and Hughes, Timothy, additional

Published
2018
Full Text
View/download PDF

12. Familial clustering of haematological malignancies: harbingers of wider germline cancer susceptibility

Author

Scott, Hamish S., primary, Brown, Anna L., additional, Hiwase, Devendra, additional, Schreiber, Andreas W., additional, Feng, Jinghua, additional, Babic, Milena, additional, Poplawski, Nicola, additional, Fine, Miriam, additional, Rawlings, Lesley, additional, Branford, Susan, additional, Fuller, Stephen, additional, Lewis, Ian, additional, D’Andrea, Richard J., additional, and Hahn, Christopher N., additional

Published
2017
Full Text
View/download PDF

13. The challenges of identifying mosaicism in haematological malignancies

Author

Scott, Hamish S., primary, Brown, Anna L., additional, Hiwase, Devendra, additional, Schreiber, Andreas W., additional, Feng, Jinghua, additional, Babic, Milena, additional, Moore, Sarah, additional, Geoghegan, Joel, additional, Parker, Wendy, additional, Branford, Susan, additional, and Hahn, Christopher N., additional

Published
2017
Full Text
View/download PDF

24. RNA-Based Targeted Gene Sequencing Improves the Diagnostic Yield of Mutant Detection in Chronic Myeloid Leukemia

Author

Naranie Shanmuganathan, Carol Wadham, Daniel Thomson, Nur Hezrin Shahrin, Chloe Vignaud, Vanessa Obourn, Shalini Chaturvedi, Feng Yang, Jinghua Feng, Verity Saunders, Chung H. Kok, David Yeung, Rob M. King, Rosalie R. Kenyon, Ming Lin, Paul Wang, Hamish Scott, Timothy Hughes, Andreas W. Schreiber, Susan Branford, Shanmuganathan, Naranie, Wadham, Carol, Thomson, Daniel, Shahrin, Nur Hezrin, Vignaud, Chloe, Obourn, Vanessa, Chaturvedi, Shalini, Yang, Feng, Feng, Jinghua, Saunders, Verity, Kok, Chung H, Yeung, David, King, Rob M, Kenyon, Rosalie R, Lin, Ming, Wang, Paul, Scott, Hamish, Hughes, Timothy, Schreiber, Andreas W, and Branford, Susan

Subjects
validation, variants, joint-consensus-recommendation, association, High-Throughput Nucleotide Sequencing, mutations, Pathology and Forensic Medicine, resistance, imatinib, for-molecular-pathology, Hematologic Neoplasms, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Mutation, Humans, RNA, cancer, Molecular Medicine, guidelines, Retrospective Studies
Abstract

Mutation detection is increasingly used for the management of hematological malignancies. Prior whole transcriptome and whole exome sequencing studies using total RNA and DNA identified diverse mu-tation types in cancer-related genes associated with treatment failure in patients with chronic myeloid leukemia. Variants included single-nucleotide variants and small insertions/deletions, plus fusion transcripts and partial or whole gene deletions. The hypothesis that all of these mutation types could be detected by a single cost-effective hybridization capture next-generation sequencing method using total RNA was assessed. A method was developed that targeted 130 genes relevant for myeloid and lymphoid leukemia. Retrospective samples with 121 precharacterized variants were tested using total RNA and/or DNA. Concordance of detection of precharacterized variants using RNA or DNA was 96%, whereas the enhanced sensitivity identified additional variants. Comparison between 24 matched DNA and RNA samples demonstrated 95.3% of 170 variants detectable using DNA were detected using RNA, including all but one variant predicted to activate nonsense-mediated decay. RNA identified an addi-tional 10 variants, including fusion transcripts. Furthermore, the true effect of splice variants on RNA splicing was only evident using RNA. In conclusion, capture sequencing using total RNA alone is suitable for detecting a range of variants relevant in chronic myeloid leukemia and may be more broadly applied to other hematological malignancies where diverse variant types define risk groups. Refereed/Peer-reviewed

Published
2022
Full Text
View/download PDF

25. Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study

Author

Devendra K Hiwase, John Taper, Carly Levetan, Ann Solterbeck, William Roberts, James D'Rozario, Anthony Richard Powell, Robert Traficante, Luke R. Anderson, Timothy P. Hughes, Ian Irving, Peter Tan, David T Yeung, Susan Branford, Othon L Gervasio, Matthew Wright, Hiwase, Devendra, Tan, Peter, D'Rozario, James, Taper, John, Powell, Anthony, Irving, Ian, Wright, Matthew, Branford, Susan, Yeung, David T, Anderson, Luke, Gervasio, Othon, Levetan, Carly, Roberts, Will, Solterbeck, Ann, Traficante, Robert, and Hughes, Timothy

Subjects
Adult, Male, Oncology, Cancer Research, medicine.medical_specialty, medicine.drug_class, Dasatinib, Tyrosine kinase inhibitor, Antineoplastic Agents, Drug Administration Schedule, Tyrosine-kinase inhibitor, 03 medical and health sciences, 0302 clinical medicine, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, hemic and lymphatic diseases, Internal medicine, medicine, Clinical endpoint, Humans, Adverse effect, Protein Kinase Inhibitors, neoplasms, Aged, business.industry, Chronic myeloid leukemia, Myeloid leukemia, Imatinib, Hematology, Middle Aged, Protein-Tyrosine Kinases, Nilotinib, Pyrimidines, Treatment Outcome, 030220 oncology & carcinogenesis, Imatinib Mesylate, Female, business, Tyrosine kinase, 030215 immunology, medicine.drug
Abstract

usc Background: Some patients receiving a tyrosine kinase inhibitor (TKI) for the first-line treatment of chronic phase chronic myeloid leukemia (CML-CP) experience intolerable adverse events. Management strategies in-clude dose adjustments, interrupting or discontinuing therapy, or switching to an alternative TKI. Methods: This multicenter, single-arm, Phase IIIb study included CML-CP patients intolerant of, but responsive to, first-line treatment with imatinib or dasatinib. All patients were switched to nilotinib 300 mg bid for up to 24 months. The primary endpoint was achievement of MR4.5 (BCR-ABL transcript level of ≤ 0.0032% on the International Scale) by 24 months. Results: Twenty patients were enrolled in the study (16 imatinib-intolerant, 4 dasatinib-intolerant); which was halted early because of low recruitment. After the switch to nilotinib 300 mg bid, MR4.5 at any time point up to month 24 was achieved in 10 of 20 patients (50%) in the full analysis set. Of the non-hematological adverse events associated with intolerance to prior imatinib or dasatinib, 74% resolved within 12 weeks of switching tonilotinib 300 mg bid. Conclusion: Nilotinib 300 mg bid shows minimal cross intolerance in patients with CML-CP who have prior toxicities to other TKIs and can lead to deep molecular responses. Refereed/Peer-reviewed

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results